News
SAGE
--
0.00%
--
Biotech Stock Roundup: GILD's UC Drug Approval, REGN's COVID-19 Antibody Data & More
Zacks.com · 2d ago
Is SAGE Stock A Buy or Sell?
Insider Monkey · 3d ago
Sage (SAGE), Biogen Report Positive Data on Essential Tremor Study
Zacks · 4d ago
DJ Neurology Drug Study Does Little for Sage Therapeutics, or Its Partner Biogen -- Barrons.com
Dow Jones · 5d ago
SAGE Therapeutics (SAGE) Receives a Buy from Oppenheimer
SmarterAnalyst · 5d ago
Biogen and Sage trade lower despite positive essential tremor trial
Both Biogen ([[BIIB]] -1.7%) and Sage Therapeutics ([[SAGE]] -4.0%) have failed to win investor interest today despite their pre-market announcement of positive top-line results from a mid-stage study evaluating SAGE-324 in the
Seekingalpha · 5d ago
Sage Stock Trips As Analysts Question Longevity Of Biogen-Partnered Drug
Investor's Business Daily · 5d ago
Sage-Biogen Essential Tremor Candidate Hits Primary Endpoint Goal, But 38% Of People Drop Out
Benzinga · 5d ago
Sage Therapeutics/Biogen's SAGE-324 meets primary endpoint in essential tremor study
Sage Therapeutics (SAGE) and Biogen (BIIB) announce topline results from Phase 2 KINETIC study evaluating SAGE-324 in the treatment of people with essential tremor ((ET)).The study (n=67 full analysis set)
Seekingalpha · 5d ago
Analysts Offer Insights on Healthcare Companies: SAGE Therapeutics (SAGE) and Revolution Medicines (RVMD)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on SAGE Therapeutics (SAGE) and Revolution Medicines (RVMD). SAGE
SmarterAnalyst · 5d ago
Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of people with essential tremor (ET). The study (n=67 full analysis set) achieved its p...
Business Wire · 6d ago
DJ Sage Therapeutics, Biogen Sees Positive Results for Essential Tremors Treatment
Dow Jones · 6d ago
Sage Falls as Some Patients Drop Out of Tremor Treatment Study
Nearly 40% of patients left a Sage Therapeutics study of a treatment for tremors due to side effects.
TheStreet.com · 6d ago
9 IPOs To Watch For This Week
For the week of July 14, 2014, there are nine IPOs slated to open for trading, including Medical Transcription Billing (NASDAQ: MTBC), previously expected to open last Thursday.
Benzinga · 04/09 19:17
Provention Bio downgraded on FDA feedback, Citi sizes up Zuranolone success on Sage, and more in today’s analyst action
The FDA feedback on an upcoming regulatory review and differing opinions on commercialization prospects of key therapies are some of the reasons for analysts to change their outlook on stocks
Seekingalpha · 04/09 13:11
Implied Volatility Surging for Sage Therapeutics (SAGE) Stock Options
Zacks.com · 04/08 00:42
Top Analyst Upgrades and Downgrades: AbbVie, Alcoa, Applied Materials, Fox, Merck, Paychex, ViacomCBS and More
247WallSt.com · 04/07 12:47
Knocked Down, These 3 Stocks May Rise Again
GuruFocus News · 04/05 13:06
The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week
Biotech stocks reversed course and ended lower in the week ended March 26, drawing inspiration from the broader market weakness. The earnings news flow was confined to micro- and small-cap companies. Five biopharma companies listed their shares on the Nasd...
Benzinga · 03/27 14:40
Webull provides a variety of real-time SAGE stock news. You can receive the latest news about SAGE through multiple platforms. This information may help you make smarter investment decisions.
About SAGE
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.